ReviewWorld journal of gastroenterology2014
Adjuvant therapy in pancreatic cancer.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis.Medicine · 2020 · on this mapPooled it
- FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.PloS one · 2015Trial
- MicroRNAs as the critical regulators of epithelial mesenchymal transition in pancreatic tumor cells.Heliyon · 2024Review
- TRIM50 Suppresses Pancreatic Cancer Progression and Reverses the Epithelial-Mesenchymal TransitionFrontiers in oncology · 2021Article
- Article
- Functional genetic variants ofJournal of Cancer · 2020Article
- Long-term survival after surgery of pancreatic primary squamous cell carcinoma: A case report and literature review.Clinical case reports · 2019Article
- Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.Targeted oncology · 2019Article
- Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance.Translational oncology · 2018Article
- High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study.Annals of medicine and surgery (2012) · 2018Article
- Identification of Sox6 as a regulator of pancreatic cancer development.Journal of cellular and molecular medicine · 2018Article
- Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.Oncotarget · 2018Article
- Potential functions and implications of circular RNA in gastrointestinal cancer.Oncology letters · 2017Article
- Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma.Oncotarget · 2017Article
- Activator protein 1 promotes gemcitabine-induced apoptosis in pancreatic cancer by upregulating its downstream target Bim.Oncology letters · 2016Article
- Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: results of a multicenter cohort study on 196 patients.Surgical endoscopy · 2016Article
- The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.BMC surgery · 2015Article
- MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.Oncotarget · 2015Article
- Pancreatic cancer incidence and mortality patterns in China, 2011.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pancreatic cancer remains one of the leading causes of cancer related death worldwide with an overall five-year survival of less than 5%. Potentially curative surgery, which alone can improve 5-year survival to 10%, is an option for only 10%-20% of patients at presentation owing to local invasion of the tumour or metastatic disease. Adjuvant chemotherapy has been shown to improve 5-year survival to 20%-25% but conflicting evidence remains with regards to chemoradiation. In this article we review the current evidence available from published randomised trials and discuss ongoing phase III trials in relation to adjuvant therapy in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.